Recombinant CD274 (Atezolizumab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原 See all CD274 (Atezolizumab Biosimilar) products
- CD274 (Atezolizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This CD274 (Atezolizumab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody
- 特异性
- The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
- 产品特性
- Recombinant Humanized IgG1 Monoclonal Antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody atezolizumab biosimilar was produced in the atezolizumab biosimilar CHO stable cell line.
- 亚型
- IgG1 kappa
-
anti-CD274 (Atezolizumab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- CD274 (Atezolizumab Biosimilar)
- Abstract
- CD274 (Atezolizumab Biosimilar) 产品
- 别名
- B7-H antibody, B7H1 antibody, PD-L1 antibody, PDCD1L1 antibody, PDCD1LG1 antibody, PDL1 antibody, CD274 molecule antibody, CD274 antibody
- 物质类
- Biosimilar
- 背景
-
What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab.
PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
-
You are here:
